Financial Data and Key Metrics Changes - Revenue for Q3 2023 was $40.8 million, representing a 23% increase year-over-year, impacted by lower-than-anticipated demand due to patient travel and vacations [10][22] - Year-to-date revenue growth was 36%, significantly above foot-and-ankle peers, with an updated full-year revenue guidance of $182 million to $186 million, reflecting a 30% increase over 2022 [7][11][24] - Gross margin decreased to 80.4% from 81.6% year-over-year, primarily due to changes in product mix and increased overhead [23] Business Line Data and Key Metrics Changes - Sold 6,459 Lapiplasty procedure kits in Q3, a 13% increase compared to the same quarter last year [22] - Record blended average selling price of $6,311 per Lapiplasty kit, up 9% year-over-year, driven by market adoption of complementary products [10][22] - Active surgeon users increased to 2,691, up 21% year-over-year, with a trailing 12-month surgeon utilization average of 10.6 kits per active surgeon [10][15] Market Data and Key Metrics Changes - Approximately 6.3% penetration of the estimated 450,000 annual surgical bunion corrections in the U.S., up from 5% in Q3 2022 [9] - The company identified a $5 billion U.S. market for bunion surgery, with only 450,000 surgeries performed annually, indicating significant growth potential [8] Company Strategy and Development Direction - The company continues to execute its strategic plan, focusing on expanding market penetration through new product launches, including SpeedPlate and Micro-Lapiplasty [7][12][20] - Investments in direct sales channels and patient awareness initiatives are expected to drive growth and improve market share [13][15] - The company aims to maintain a strong focus on bunion and related midfoot procedures while expanding its product portfolio [26][27] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in a strong Q4 rebound, citing record surgeon additions in September and continued strength into October [36][56] - The company anticipates a positive contribution from new product launches in 2024, including SpeedPlate and Hammertoe systems, which are expected to enhance market opportunities [26][27] - Management acknowledged the impact of summer seasonality on Q3 results but remains optimistic about the fundamentals of the business [52][66] Other Important Information - The company has a robust product development pipeline with 10 new innovations slated for launch over the next 12 months [20] - Cash, cash equivalents, and marketable securities totaled $128.2 million as of September 30, 2023, providing a strong balance sheet for strategic investments [23] Q&A Session Summary Question: Impact of guidance cut by $10 million at the midpoint - Management noted that both fewer surgeons and delays in SpeedPlate contributed to the guidance cut, with unexpected summer seasonality affecting case volumes [29][30] Question: Confidence in Q4 rebound despite summer seasonality - Management highlighted strong surgeon additions in September and October, along with historical trends of Q4 being the highest revenue quarter [36][56] Question: Lower expected new surgeon additions for next year - Management explained that while the pace of new surgeon additions may slow, they expect increased utilization from the existing surgeon base and new product adoption to drive growth [39][40] Question: Decision to delay full launch of SpeedPlate - The delay was due to the opportunity to enhance the product based on early feedback, aiming for broader appeal across various surgical applications [42] Question: Gross margin performance and future expectations - Management indicated that gross margin fluctuations are common due to product mix and overhead, but they expect to maintain margins above 80% [55]

or UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40355 Treace Medical Concepts, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1052611 (State ...

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q2 2023 Results Conference Call August 8, 2023 4:30 PM ET Company Participants Julie Dewey - Chief Communications & Investor Relations Officer John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Lilia-Celine Breton Lozada - JPMorgan Ryan Zimmerman - BTIG Operator Good day and thank you for standing by. Welcome to the Treace Medical Concepts' Second Quarter 2023 Earnings Conference Call. At this time, all participa ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40355 Treace Medical Concepts, Inc. (Exact name of registrant as specified in its charter) 100 Palmetto Park Place Ponte V ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40355 Treace Medical Concepts, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1052611 (State or ...

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Vivian Cervantes - IR, Gilmartin Group John Treace - CEO Mark Hair - CFO Conference Call Participants Robbie Marcus - JPMorgan Drew Ranieri - Morgan Stanley Rick Wise - Stifel Ryan Zimmerman - BTIG Rich Newitter - Truist Securities George Sellers - Stephens Inc. Operator Good day and thank you for standing by. Welcome to the Treace Medical First Quarter 2023 Earnings Call. At this time al ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-40355 TREACE MEDICAL CONCEPTS, INC. (Exact name of Registrant as specified in its Charter) | Delaware | 47-1052611 | | --- | --- | | (State or other jurisdiction of | (I.R.S. Employer | | incorporation or organization) | Identification No.) | | 100 Palmetto Park Place | | | ...

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q4 2022 Earnings Conference Call March 7, 2023 4:30 PM ET Company Participants Vivian Cervantes - Investor Relations, Gilmartin Group John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Robbie Marcus - JPMorgan Drew Ranieri - Morgan Stanley Ryan Zimmerman - BTIG Operator Hello, and welcome to Treace Medical Concepts Fourth Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen only m ...

Treace Medical Concepts, Inc. (NASDAQ:TMCI) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Vivian Cervantes - Investor Relations, Gilmartin Group John Treace - Chief Executive Officer Mark Hair - Chief Financial Officer Conference Call Participants Lilia-Celine Breton Lozada - JPMorgan Andrew Ranieri - Morgan Stanley Ryan Zimmerman - BTIG Rick Wise - Stifel Vivian Cervantes Good afternoon, everyone, and welcome to our Third Quarter 2022 Earnings Conference Call. Participat ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-Q (Mark one) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from___ to___ Commission file number: 001-40355 Treace Medical Concepts, Inc. (Exact name of registrant as specified in its charter) Delaware 47-1052611 (State ...